Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study
PURPOSEDihydropyrimidine dehydrogenase (DPD) deficiency, an autosomal recessive metabolic disorder, causes a considerable deficit in the patient's metabolism of fluoropyrimidine drugs, most notably 5-fluorouracil (5-FU) and capecitabine. There is a higher frequency of severe toxicities after a fluor...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society of Clinical Oncology
2025-11-01
|
| Col·lecció: | JCO Global Oncology |
| Accés en línia: | https://ascopubs.org/doi/10.1200/GO-25-00442 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|